IMMUNOME INC (IMNM)

Company Profile

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. The company is headquartered in Exton, Pennsylvania and currently employs 37 full-time employees. The company went IPO on 2020-10-02. The Company’s portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, targeted effectors, radioligand therapies and ADCs. Its proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of antibodies and targets. Its lead discovery programs include Oncology (IMM-ONC-01) and SARS-CoV-2 (IMM-BCP-01). Its IMM-ONC-01 is its lead oncology program targets interleukin 38 (IL-38), which is a negative regulator of inflammation capable of promoting tumor evasion of the immune system. The firm is developing an antibody cocktail derived from the B cells of COVID-19 patients who exhibited high neutralizing titers. IMM-BCP-01 targets non-overlapping regions of the Spike protein of SARS-CoV-2, which include highly conserved, subdominant epitopes. The IMM-BCP-01 program is focused on the variants of SARS-CoV-2.

Company Info

IMMUNOME INC

665 Stockton Drive, Suite 300

Exton PENNSYLVANIA 19341

P: 16103213700

CEO: Purnanand D. Sarma

Employees: 37

Website: https://immunome.com/